As early adopters of daily home hemodialysis with the NxStage System One, each of the patients arrived at the decision to try NxStage at various stages in their treatment. All four patients are followed by Satellite WellBound Centers, a NxStage partner that established the first program in NxStage's IDE clinical study in 2003. These patients--Craig, Everett, Carl and Susan--began training with the NxStage System One on
Carl emphasizes the significant health benefits of home hemodialysis
For Carl, who was diagnosed with kidney failure in 1996, in-center dialysis had been a physically grueling as well as intensely time-consuming process. "After starting on NxStage, I felt like a new person compared to when I was doing in-center hemo," stated Carl. Five years later, Carl is still feeling well and enjoying the benefits of daily home hemodialysis with the NxStage System One.
Everett knew there had to be a better way
Following two failed kidney transplants, Everett relied upon in-center dialysis treatments that lasted anywhere from two to three and a half hours. Then he learned about a new treatment based on a portable hemodialysis machine. Five years later, Everett does his hemodialysis at home six times a week. "I work treatments into my life, not the other way around," he insists. He's gone back to playing basketball, a sport he always loved but hadn't played in years due to fatigue.
Craig has taken his dialysis on the road
Craig has been dialysis-dependent since he was 19. When he heard about a new portable dialysis therapy that would enable him to do his treatments at home on a more frequent basis, Craig immediately knew the treatment option was for him. "I bugged my doctor for a year, incessantly, until it was available," he says. In
Susan felt NxStage "gave me my life back"
When Susan's kidneys failed, she was forced to quit her job and go on permanent disability. Moreover, the fatigue and pain that ensued from her in-center dialysis treatments were completely incapacitating. After only one treatment on the NxStage System One, she recognized a difference in the way she felt. Just short of four years into her treatment with NxStage, Susan received a kidney transplant. Susan credits NxStage with helping her body feel healthy enough to sustain a transplanted kidney.
"Our research and experience have shown that more frequent dialysis provides patients with improved health outcomes such as reduced hospitalizations and improved mortality rates," stated John Moran, MB, BS, FRACP, FASN, senior vice president of clinical affairs for Satellite Healthcare and WellBound. "Daily home dialysis with NxStage is a tremendous treatment option for patients, and one from which many more dialysis patients could benefit."
"NxStage's founding mission is to give patients access to a range of dialysis therapies via the System One that deliver health benefits and meaningfully improve their quality of life," stated
About NxStage Medical
NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in
The patient testimonials included in this release are examples of patient experiences on daily home hemodialysis with the NxStage System One. All patient experiences will vary, and there can be no assurance that all patients will experience these benefits. All hemodialysis involves some risk, and patients are encouraged to speak with their physicians to see if home dialysis with the NxStage System One is right for them.
Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including, but not limited to: market acceptance of the NxStage System One, the anticipated impact and results of daily hemodialysis, and other factors that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended
Contact: Kristen K. Sheppard, Esq VP, Investor Relations ksheppard@nxstage.com Jane Hauser Schwartz Communications nxstage@schwartz-pr.com 781-684-0770
SOURCE NxStage Medical, Inc.